上海邁邦生(sheng)(sheng)物科技有(you)限公司（簡稱“邁邦生(sheng)(sheng)物”或“Medium Bank”）于(yu)2019年在張江藥谷成(cheng)立，是一家國(guo)際的專注于(yu)學(xue)成(cheng)分限定培(pei)養(yang)(yang)基(ji)（CD, Chemical Defined）產(chan)品的研發及(ji)生(sheng)(sheng)產(chan)、客戶(hu)化(hua)培(pei)養(yang)(yang)基(ji)的優化(hua)開發（MOD, Medium Optimization & Development）服(fu)務及(ji)大(da)規模干粉/液體培(pei)養(yang)(yang)基(ji)代工(gong)生(sheng)(sheng)產(chan)（OEM）等生(sheng)(sheng)物醫(yi)藥工(gong)藝綜合(he)解決(jue)方案的服(fu)務商(shang)。

邁(mai)(mai)邦(bang)生(sheng)物(wu)自創(chuang)立以來，憑借豐(feng)富的(de)創(chuang)新(xin)研發(fa)和(he)技術服務能(neng)力，產(chan)品及服務已涵(han)蓋CHO細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)、雜交瘤/骨髓瘤細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)、HEK293細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)、昆蟲細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)、病毒疫苗細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)及T細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)/干細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)等各(ge)大細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)平臺，多數產(chan)品性(xing)能(neng)及優(you)化開(kai)發(fa)服務表現均(jun)已優(you)于國際細(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)培養基公(gong)司。2021年(nian)，邁(mai)(mai)邦(bang)生(sheng)物(wu)GMP標(biao)準建(jian)設的(de)MFG1一期產(chan)能(neng)正式投(tou)產(chan)；MFG2二期量產(chan)化基地(di)建(jian)設持續(xu)推進(jin)中；2022年(nian)，零缺陷通過ISO13485質量體系(xi)認證，完(wan)成生(sheng)產(chan)管(guan)理及質量體系(xi)的(de)再升級(ji)，已有(you)數十家生(sheng)物(wu)醫藥企業(ye)完(wan)成了對邁(mai)(mai)邦(bang)生(sheng)物(wu)生(sheng)產(chan)基地(di)的(de)現場審計。

目前，邁邦生(sheng)(sheng)物的(de)產(chan)品及(ji)服務已在國內(nei)外(wai)超過300家(jia)(jia)生(sheng)(sheng)物醫藥企(qi)(qi)業(ye)(ye)得(de)到驗證(zheng)，并(bing)獲得(de)行業(ye)(ye)內(nei)數(shu)百家(jia)(jia)生(sheng)(sheng)物醫藥企(qi)(qi)業(ye)(ye)的(de)認可(ke)、信賴和支持。客戶(hu)涵蓋單抗、融(rong)合蛋白、動物或人用(yong)(yong)疫苗、IVD、細(xi)胞基因治療、細(xi)胞培養肉(rou)等多種類生(sheng)(sheng)物醫藥企(qi)(qi)業(ye)(ye)。產(chan)品已被國內(nei)外(wai)多家(jia)(jia)生(sheng)(sheng)物醫藥企(qi)(qi)業(ye)(ye)廣泛(fan)應用(yong)(yong)于生(sheng)(sheng)物醫藥研發、臨床申報及(ji)商品化生(sheng)(sheng)產(chan)等不同階段(duan)。